REGENXBIO Inc., a biotechnology company specializing in gene therapy, announced its participation in the Baird 2026 Global Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. These events will feature fireside chats on September 15 and 16, 2026, in New York, with live webcasts available on REGENXBIO's website. The company is advancing late-stage gene therapy treatments for rare and retinal diseases, aiming to improve healthcare delivery for millions. This participation highlights REGENXBIO's ongoing efforts to engage investors and showcase its pipeline progress.
Bank of America upgraded DraftKings stock to Buy from Neutral, citing reduced risks from prediction markets and a favorable risk-reward at current prices. DraftKings shares rose 5% following the upgrade, while competitors Flutter Entertainment and MG...
Vertiv has named Michael Resha as Executive Vice President of Manufacturing, Logistics, and Operational Excellence, succeeding Anders Karlborg who moves to a new role. Resha will lead global manufacturing and logistics efforts to scale operations and...
Bitmine increased its Ether (ETH) holdings by 15,112 coins last week, bringing its total to 6,016,414 ETH. This accumulation highlights Bitmine's ongoing investment in Ethereum, signaling confidence in the digital asset's future. The move may influen...
Cerrado Gold (CRDOF) has been upgraded to a Buy rating due to improved production at its Minera Don Nicolas (MDN) mine, which reached 15,415 gold equivalent ounces in Q2, supporting the annual target of 50,000 GEO. However, cost control remains a cha...
Rapid Dose Therapeutics announced it will issue common shares to settle $142,067.63 of accrued interest on its secured convertible notes by October 15, 2026. The notes, originally issued in 2023, bear 18% annual interest payable quarterly in shares a...
